Epidural Spinal Cord Stimulation for Restoring Walking in Spinal Cord Injury
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 16 and 70 years old?
Source: NCT07306052, who can take part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Second Affiliated Hospital, Zhejiang University, School of Medicine
- Trial code
- NCT07306052
- Record updated
- 29 May 2026
- Original description
The goal of this clinical trial is to evaluate the safety and effectiveness of Epidural Electrical Stimulation (EES) combined with rehabilitation training for the reconstruction of walking in patients with chronic spinal cord injury (SCI) classified as AIS B-D. The main questions it aims to answer are:Read full original descriptionShow less
Safety and Efficacy of Epidural Spinal Cord Stimulation for Restoring Walking in Spinal Cord Injury
The goal of this clinical trial is to evaluate the safety and effectiveness of Epidural Electrical Stimulation (EES) combined with rehabilitation training for the reconstruction of walking in patients with chronic spinal cord injury (SCI) classified as AIS B-D. The main questions it aims to answer are:
Does the intervention of EES combined with rehabilitation significantly improve walking capacity? Is the combined intervention a safe approach for this patient population? Researchers will compare participants' functional assessments before EES implantation and at 2, 4, 7, 10, and 13 months post-implantation to evaluate the longitudinal effects. The primary assessments include the Walking Index for Spinal Cord Injury II (WISCI II), the Spinal Cord Independence Measure (SCIM III), and the adverse event. Secondary outcome measures encompass the International Standards for Neurological Classification of Spinal Cord Injury (ISNCSCI), the Functional Independence Measure (FIM), the Modified Ashworth Scale (MAS), the Penn Spasm Frequency Scale, the 10-Meter Walk Test (10mWT), the 6-Minute Walk Test (6minWT), and pain Visual Analogue Scale (VAS) scores. Neurophysiological and imaging evaluations, including electromyography (EMG), motor evoked potentials (MEPs), somatosensory evoked potentials (SEPs), and positron emission tomography-computed tomography (PET-CT), will be conducted preoperatively and at 6 months postoperatively to explore the mechanisms of neuroplasticity.
Participants will:
Undergo surgical implantation of an EES device. Receive personalized EES parameter programming combined with rehabilitation training (≥2 hours daily) post-operatively.
Complete a series of standardized functional and clinical outcome assessments at scheduled follow-up intervals.
Undergo scheduled neurophysiological and metabolic imaging studies. Report any adverse events throughout the study duration.
Inclusion: Age between 16 and 70 years; Diagnosed with traumatic spinal cord injury for ≥ 6 months and ≤ 60 months; American Spinal Injury Association Impairment Scale (AIS) grade B-D; Spinal cord injury level above T10; Walking Index for Spinal Cord Injury II (WISCI II) score ≤ 13; Completion of a standard conventional rehabilitation program prior to enrollment; Preserved upper limb function sufficient for self-propelling a manual wheelchair; Sitting balance grade ≥ 1; Ability to elicit clear electromyographic responses in lower limb muscles (e.g., rectus femoris, biceps femoris, gastrocnemius, tibialis anterior) upon transcutaneous electrical spinal cord stimulation at the T12-L1 vertebral levels; Willingness to voluntarily participate, and commitment to compliance with all necessary postoperative rehabilitation, assessments, and follow-up visits.
Exclusion: History of myocardial infarction or stroke within the past 6 months; Diagnosis of psychiatric disorders with active suicidal ideation or risk; Bleeding tendency or coagulopathy (prothrombin time ≥18 seconds); History of alcohol or substance abuse or dependence; Intellectual disability, cognitive impairment, or personality disorders; Other chronic medical conditions that may interfere with rehabilitation (e.g., unhealed severe fractures, hepatic or renal failure, severe anemia, etc.); Implantation of cardiac pacemakers, cardioverters, or defibrillators; Any other condition deemed inappropriate for participation by the investigators; Current pregnancy or planned pregnancy during the study period.